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Green tea polyphenol sensing
By Hirofumi TACHIBANA*1,*2,*3,†
(Communicated by Tatsuo SUDA, M.J.A.)
Abstract: Green tea polyphenols have emerged over the past two decades as an important
dietary factor for health promotion. There is considerable evidence that tea polyphenols, in
particular (!)-epigallocatechin-3-gallate (EGCG) inhibit carcinogenesis. However, the mechanisms
for the cancer-preventive activity of EGCG are not completely characterized and many features
remain to be elucidated. Recently we have identiﬁed a cell-surface EGCG receptor and the relating
molecules that confer EGCG responsiveness to many cancer cells at physiological concentrations.
Here, we review some of the reported mechanisms for the cancer chemopreventive action of EGCG
and provide an overview of several molecules that sense and manage the physiological functions of
EGCG.
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Introduction
Phytochemicals, compounds made from fruits,
vegetables, and grains, possess anti-cancer properties
and represent a promising therapeutic approach for
the prevention and treatment of many cancers. An
extensive amount of research is being conducted on
the beneﬁts of phytochemicals. Indeed, there are a
number of clinical trials that have evaluated these
natural products for their eﬃcacy in preventing
disease. Many food items, beverages and dietary
constituents have shown anticancer and cancer-
preventive activities. Tea is one of the most widely
consumed beverages in the world after water. Green
tea, black tea, and oolong tea are all derived from the
dried leaves of the plant Camellia sinensis and contain
an assortment of compounds, the most signiﬁcant
components of which are phytochemicals. Among all
teas consumed in the world, green tea is best studied
for its health beneﬁts. It has been demonstrated that
tea constituents exhibit various biological and phar-
macological properties such anti-carcinogenic, anti-
oxidative, anti-allergic, anti-virus, anti-hypertensive,
anti-atherosclerosis, anti-cardiovascular disease and
anti-hypercholesterolemic activities.1)–8) Principles
for these activities were shown to be a group of poly-
phenols, catechin. The major green tea catechins are
(!)-epigallocatechin-3-gallate (EGCG), (!)-epigallo-
catechin (EGC), (!)-epicatechin-3-gallate (ECG) and
(!)-epicatechin (Fig. 1). Tea catechins are character-
ized by the dihydroxyl or trihydroxyl substitutions on
the B ring and the m-5,7-dihydroxyl substitutions on
the A ring. The B ring seems to be the principal site of
antioxidant reactions and the antioxidant activity is
further increased by the trihydroxyl structure in the D
ring (gallate) in EGCG and ECG. A typical green tea
beverage, prepared in a proportion of 1g leaf to 100ml
water in a 3-min brew, usually contains 250–350mg
tea solids, and catechins account for 30–42% of the dry
weight of the solids.9) Among the green tea catechins,
EGCG is the most abundant, representing 916.5wt%
of the water extractable fraction of green tea leaves,
and most active catechin in various kinds of physio-
logical activities. Because EGCG is not found to a
plant except tea, EGCG is regarded as a constituent
characterizing green tea. In this review we focused
the current understanding of EGCG sensing mecha-
nisms by which EGCG exerts the beneﬁcial health
eﬀects.
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The cancer-preventive activities of tea and
tea constituents have also been studied in diﬀerent
models of oral–digestive tract carcinogenesis.10) In
a review of the 147 papers published by 2008, 133
described cancer-preventive or inhibitory eﬀects.11)
In the ApcMin/D mouse model of intestinal tumori-
genesis, EGCG solution given as the sole source of
drinking ﬂuid, inhibited the spontaneous develop-
ment of small intestinal tumours.12) In a model using
a food carcinogen, PhIP (2-amino-1-methyl-6-phen-
ylimidazo[4,5-6]pyridine), to induce colon carcino-
genesis in rats, treatment with EGCG during the
post-initiation stage for 15 weeks reduced ACF
formation by 71% compared with water-treated
controls.13) We also found that tumor growth of
B16 melanoma cells was signiﬁcantly retarded in
0.1% EGCG-administered C57BL/6N mice.14)
Cancer prevention by tea consumption
The eﬀects of tea consumption on the risk of
human cancer have been investigated in many
epidemiological studies, but the results have been
inconclusive.10) A literature search in the PubMed
database for papers published up to 2008 showed 127
case–control studies and 90 cohort studies on the
relationship between tea consumption and the risk
for colon, lung, stomach, breast, prostate, ovarian,
pancreatic, kidney, bladder and other cancers.11) Of
these studies, only 51 case–control studies and 19
cohort studies showed an inverse association between
tea consumption and cancer risk, suggesting a cancer-
preventive eﬀect of tea, whereas other studies showed
no such association. The inconsistent results of the
epidemiological studies were probably due to diﬀer-
ent confounding factors, diﬃculties in quantifying
tea consumption, varied cancer aetiology in diﬀerent
populations and population heterogeneity. When
these factors were eﬀectively managed, a clearer
relationship between tea consumption and cancer
risk was observed in several studies. A preliminary
double-blind, placebo-controlled study on oral ad-
ministration of green tea catechins in volunteers with
high-grade prostate intraepithelial neoplasia (HG-
PIN) suggested a chemopreventive activity of EGCG
on prostate cancer.15)
Anti-oxidant and pro-oxidant properties
of EGCG
EGCG and other tea polyphenols are well
known for their anti-oxidant activities. Among tea
catechins, EGCG is the most eﬀective in reacting
with the majority of reactive oxygen species (ROS).
Tea polyphenols are also strong chelators of metal
ions; the chelation of free metal ions prevents the
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Fig. 1. Chemical structures of green tea catechins.
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compounds. Indeed, they have been demonstrated to
inhibit carcinogen-induced DNA damage and tumor
promoter-induced oxidative stress.16) These results
are consistent with the commonly mentioned idea
that tea prevents cancer because tea polyphenols are
anti-oxidants. However, it is unclear whether this is a
general mechanism for cancer prevention, especially
in human carcinogenesis.
There are two major problems in extrapolating
results observed in cell lines to animal models. (1)
The concentration of the test compound used in cell
line systems, for example, EGCG at 20–100µM, or
higher concentrations, are much higher than those
observed in the plasma or tissues in experimental
animals or humans after ingestion of tea or related
tea preparations.17) (2) The oxygen partial pressure
in a cell culture system (160mmHg) is much higher
than that in the blood or tissues (<40mmHg). Under
cell culture conditions, EGCG is not stable, with a
half-life less than 2h.18) The half-life can be extended
several folds by the addition of superoxide dismutase
(SOD), suggesting a role for superoxide radical in the
oxidation and polymerization of EGCG.19) Similar
to other anti-oxidants, EGCG and other tea poly-
phenols may also act as pro-oxidants. In the case of
EGCG, auto-oxidation generates superoxide anion
and hydrogen peroxide and leads to the formation
of dimers, such as theasinensins.14) The polyphenolic
structure of tea polyphenols also makes them good
donors for hydrogen bonding. For example, hydrogen
bonding of water molecules to EGCG forms a large
hydration shell, which reduces the absorption of
EGCG.20)–22) This hydrogen bonding capacity also
enables tea polyphenols to bind strongly to proteins
and nucleic acids. It is not clear whether pro-oxidants
produced by EGCG-generated reactions occur in low
oxygen partial pressure conditions in vivo in cells,
which generally have strong anti-oxidative capacity
and low oxygen partial pressure. The diﬀerence
between in vitro and in vivo systems should be
considered in studies attempting to elucidate the
mechanisms of action of EGCG.
Bioavailability of EGCG
The bioavailability and biotransformation of tea
catechins following tea ingestion has been inves-
tigated in human volunteers, and a time to reach
maximal concentration in the plasma of 1.5 to 2.5h
after consumption of decaﬀeinated green tea solids
(1.5, 3.0, and 4.5g).23) The catechins levels decreased
and were not detectable by 24h. Whereas EGCG and
ECG were not detected in the urine, 90% of the
urinary EC and EGC were excreted by 8h. Most of
the ingested EGCG apparently does not get into the
blood, and absolute EGCG is preferentially excreted
through the bile to the colon. Glucuronidation,
sulfation, methylation, and ring-ﬁssion metabolism
represent the major metabolic pathways for green tea
catechins. Plasma EC and EGC were present mainly
in the conjugated form such as glucuronide and
sulfate conjugates, whereas 77% of the EGCG was in
the free form. EGCG has also been shown to undergo
methylation. The maximum plasma concentration of
4′,4′′-di-O-methyl-EGCG is 20% that of EGCG but
the cumulative excretion of 4′,4′′-di-O-methyl-EGCG
is 10-fold higher than that of EGCG over 24h.24)
Although most of published studies in cell culture
systems used 10–100µM of EGCG, the blood level of
EGCG after consuming the equivalent of 2–3c u p s
of green tea was 0.1–0.6µM and for an equivalent of
7–9 cups was still lower than 1µM.25) The rather
poor bioavailability of tea catechins needs to be
considered when we extrapolate results obtained
in vitro to situations in vivo.
The discovery of a cell surface EGCG receptor
It should be noted that most of the eﬀects of
EGCG in cell culture systems and cell-free systems
have been obtained with considerable high concen-
trations than observed in the plasma or tissues of
animals or in human plasma after administration of
green tea or EGCG. As described previously, the
pharmacokinetic studies in humans indicate that the
peak plasma concentration after single dose of EGCG
is <1.0µM. Furthermore, the intracellular levels
of EGCG are much lower than the concentrations
observed in the extracellular levels. Searching for
high-aﬃnity proteins that bind to EGCG is the ﬁrst
step to understanding the molecular and biochemical
mechanisms of the anti-cancer eﬀects of tea poly-
phenols. Several proteins that can directly bind with
EGCG have been identiﬁed in vitro models. Using an
EGCG-conjugated aﬃnity column, two dimensional
electrophoresis and matrix-assisted laser desorption/
ionization-time-of-ﬂight mass spectroscopy, vimen-
tin,26) insulin-like growth factor 1 receptor (IGF1R),27)
Fyn,28) glucose-regulated protein 78kDa29) and
ZAP7030) are identiﬁed as high-aﬃnity EGCG bind-
ing proteins. All of these proteins were demonstrated
to be important for the inhibitory activity of EGCG
in cell lines, but higher EGCG concentrations than
the Kd values were needed. For example, vimentin
binds to EGCG with a Kd of 3.3nM, and functional
H. TACHIBANA [Vol. 87, 68studies showed that EGCG inhibited the phospho-
rylation of vimentin at Ser55 and Ser50 by Cdc2
(IC50 F 17µM). The diﬀerence in eﬀective concen-
trations is probably due to the nonspeciﬁc binding of
EGCG to other proteins, which compete with the
target proteins. Therefore, it is not clear whether the
activities observed with high EGCG concentrations
in vitro can be observed in vivo and the proposed
EGCG-binding molecules as mentioned above are
responsible for in vivo physiological activities of
EGCG.
To elucidate the detail molecular basis for the
action of EGCG, it is necessary to identify the
molecular target triggering a speciﬁc signaling of
EGCG. Studies of Toll-like receptors teach us the
principal role in the pathogens sensing and the
necessity of identiﬁcation of the speciﬁc receptor as
a signal initiator for generating cellular responses for
understanding the speciﬁc cellular signaling of foreign
or functional substances. However, the molecular
target for physiologically relevant EGCG that can
mediate its anti-cancer eﬀect still remained unknown.
We found that all-trans-retinoic acid (ATRA)
enhances the binding of EGCG to the cell surface of
cancer cells when the binding was monitored on the
basis of the increase in response units in a surface
plasmon resonance (SPR) assay.31) To identify
candidates through which EGCG inhibits cell
growth, we used a subtraction cloning strategy
involving cDNA libraries constructed from cells
treated or untreated with ATRA. We isolated a
single target that allows EGCG to bind to the cell
surface. An analysis of the DNA sequence identiﬁed
this unknown cell surface candidate as the 67-kDa
laminin receptor (67LR). In fact, the expression of
this 67LR was enhanced by ATRA treatment.
Human lung cancer A549 cells were used to
assess how eﬀectively the 67LR mediates EGCG-
mediated growth inhibition. Cells transfected with
empty vector and treated with EGCG showed no
growth inhibition (Fig. 2). However, cells transfected
with the gene encoding 67LR and treated with
EGCG demonstrated considerable inhibition as
compared with the cells treated with H2O. We next
tested whether the growth inhibitory activity of
EGCG correlates with the binding strength of EGCG
to the cell surface. We found increased binding of
EGCG to the cell surface of cells transfected with
67LR (Fig. 2). EGCG binding to the 67LR-trans-
fected cells was inhibited by treatment with an
antibody to 67LR. The predicted Kd value for the
binding of EGCG to the 67LR protein is 39.9nM.31)
Most of the 67LR protein was found to exist in
the raft fraction rather than the non-raft fraction,32)
and this distribution pattern correlated well with
the plasma membrane-associated EGCG level after
treating the cells with EGCG.33)
To investigate whether the 67LR can confer
a sensitivity to EGCG at physiologically relevant
concentrations, we treated the 67LR-transfected
A549 cells with two concentrations of EGCG (0.1
and 1.0µM); these concentrations are similar to
the amount of EGCG found in human plasma after
drinking more than two or three cups of tea. The
growth of the transfected cells was inhibited at both
of these concentrations.31) In addition, this growth-
suppressive eﬀect was completely eliminated upon
treatment with anti-67LR antibody before the
addition of EGCG.
Next, we investigated the eﬀect of oral admin-
istration of EGCG on subcutaneous tumor growth in
C57BL/6N mice challenged with 67LR-ablated B16
cells.14) We conﬁrmed both silencing of 67LR by
stable RNAi in B16 cells and attenuation of the
inhibitory eﬀect of 1µM EGCG on cell growth in
67LR-ablated B16 cells in vitro. Tumor growth was
signiﬁcantly retarded in EGCG-administered mice
implanted with the B16 cells harboring a control
shRNA, whereas tumor growth was not aﬀected by
EGCG in the mice implanted with 67LR-ablated B16
cells, suggesting that 67LR functions as an EGCG
receptor not only in vitro but also in vivo. Together,
these observations demonstrate that the cell-surface
67LR is the receptor for antitumor action of EGCG
at the physiologically relevant concentration. The
discovery of EGCG receptor as 67LR has solved some
of the discrepancies of the cancer-preventing activity
of EGCG between in vitro data and in vivo data.
The 67-kDa laminin receptor
67LR was ﬁrst discovered by three independent
laboratories in 198334)–36) through its ability to bind
to and be isolated by laminin sepharose. The receptor
bound laminin with high aﬃnity with a Kd of 2nM.34)
Consequently, this receptor was named 67LR and,
more recently, LAMR1 (laminin receptor-1). Its gene,
however, was found to encode a protein of only 37-
kDa. The discrepancy between these two molecular
weights was later resolved by showing that the 37-
kDa gene product serves as a monomeric precursor to
a 67-kDa dimmer.37) The exact composition of the 67-
kDa dimer and the process by which it is formed
remains obscure as evidence supports both a homo38)
and a heterodimer.39),40) 37/67-kDa laminin receptor
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Fig. 2. The interactions between tea constituents and 67LR-transfected cells. (A) Growth inhibitory activities of tea constituents
(indicated by bars, 5µmol/L) on A549 cells transfected with either the gene encoding 67LR (red) or vector only (purple) were
examined. (B) The interaction between tea constituents (5µmol/L) and A549 cells transfected with the 67LR vector (red line) or the
empty vector (purple line) was measured using a SPR assay.
Basophils
Allergen
Histamine release
IgE
Fig. 3. Model of possible EGCG signaling pathway for anti-allergic actions through 67LR. The suppression of MRLC phosphorylation
through the cell-surface binding to the 67LR contributes to the inhibitory eﬀect of EGCG on the histamine release from basophils.
The 67LR also mediates the EGCG-induced suppression of FcCRI expression in basophils by reducing ERK1/2 phosphorylation.
H. TACHIBANA [Vol. 87, 70was shown to be acylated by three fatty acids
(palmitate, stearate, and oleate38)) and fatty acid
synthesis is required for 67-kDa laminin receptor
formation.39) Beyond this not much is known about
what regulates the dimerization process.
Expression of the 67LR has been shown to be
upregulated in neoplastic cells compared with their
normal counterparts and directly correlate with an
enhanced invasive and metastatic potential in many
malignancies.41),42) The receptor has been implicated
in laminin-induced tumor cell attachment and
migration, as well as in tumor angiogenesis, invasion,
and metastasis.43)–45) Surface expression of the 67LR
has also been reported to be a dominant laminin-
binding protein expressed in neutrophils, macro-
phages, and monocytes, which suggests that the
receptor may play an important role in the regulation
of cell adherence via the basement membrane
laminin.46)–48) It has been reported that the expres-
sion of 67LR in mast cells is related to the adhesion to
laminin and may contribute to the tissue distribution
of mast cells and to mast cell accumulation at sites of
tissue injury and inﬂammation.49),50) 67LR has also
been shown to be able to modulate granulocyte-
macrophage colony-stimulating factor (GM-CSF)
signaling by inhibiting GM-CSF-its receptor (GMR)
complex formation through its interaction with
GMR.51) Furthermore, it has been suggested that
the 67LR expression in human T cells is upregulated
by stimulating the neuropeptides GnRH-II and
GnRH-I which trigger its homing to speciﬁc organs.52)
This protein also acts as a receptor for patho-
genic prion protein,53) cytotoxic necrotizing factor 1
from E. coli,54) Sindbis virus,55) Dengue virus,56) and
adeno-associated virus subtypes 2, 3, 8, and 9.57)
Interestingly, unmodiﬁed 37-kDa laminin receptor
precurcor (37LRP) is a ribosomal component and
homologues of this protein are found in all ﬁve
kingdoms. 37/67-kDa laminin receptor has been
shown to localize to the nucleus and interact with
histones in the eukaryotic cell nucleus.58)
Mice that are heterozygous for the Rpsatm1Ells,
LAMR1, targeted mutation are viable, fertile, and do
not display any gross behavioral abnormalities.
Homozygous null mice have an embryonic lethal
phenotype, failing to develop past embryonic days
3.5. Heterozygotes exhibit delayed embryonic growth
that normalizes postnatally (unpublished data).
The inhibition of cancer cell growth by EGCG
through the 67LR
Phosphorylation of the myosin regulatory light
chain (MRLC) at Thr18/Ser19 was shown to
regulate the association between myosin II and
ﬁlamentous actin (F-actin). The association of
myosin II with F-actin results in the formation of
stress ﬁbers in interphase cells and the contractile
ring in dividing cells. When human cervical carcino-
ma HeLa cells were incubated with EGCG, the cells
retracted and left intercellular gaps. In addition,
disappearance of the stress ﬁbers in the central cell
body was observed upon treatment with EGCG and
the MRLC phosphorylation was reduced by EGCG
treatment. The phosphorylation of MRLC at Thr18/
Ser19 has been shown to be necessary for formation
of the contractile ring in dividing cells. EGCG
treatment for signiﬁcantly increased the percentage
of cells in the G2/M phase.
To analyze whether the suppressive eﬀect of
EGCG on the MRLC phosphorylation is mediated by
the 67LR, RNAi-mediated gene silencing was utilized
to knock down the expression of the 67LR.21) EGCG
signiﬁcantly reduced the phosphorylation of MRLC
in the HeLa cells, however in the 67LR-ablated cells,
EGCG only slightly reduced the phosphorylation,
suggesting that EGCG inhibits the cancer cell growth
by reducing the MRLC phosphorylation and this
eﬀect is mediated by the 67LR. Epidemiological
studies have suggested that the consumption of green
tea may decrease colon cancer risk in woman.59) We
also found that a physiologically achievable concen-
tration of EGCG inhibited cell cycle progression of
human colon adenocarcinoma Caco-2 cells through
67LR.20)
Induction of apoptosis in myeloma and leukaemia
cells by EGCG through the 67LR
EGCG has been shown to be able to induce
growth arrest and subsequent apoptotic cell death in
multiple myeloma (MM) cells and primary patient
MM cells in vitro, while having no signiﬁcant eﬀect
on growth normal cells such as peripheral blood
mononuclear cells (PBMCs) and ﬁbroblasts.60) Treat-
ment with EGCG (33mg/kg/d) also led to signiﬁ-
cant apoptosis in human myeloma cells grown as
tumors in SCID mice. The expression of 67LR was
signiﬁcantly elevated in myeloma cell lines and
patient samples compared to normal PBMCs.
RNAi-mediated inhibition of 67LR expression re-
sulted in abrogation of EGCG-induced apoptosis
in myeloma cells, indicating that 67LR plays an
important role in mediating EGCG activity in MM
while sparing PBMCs.60) Evaluation of changes in
gene expression proﬁle indicates that EGCG treat-
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and apoptosis in MM cells by inducing the expression
of death-associated protein kinase 2, the initiators
and mediators of death receptor-dependent apoptosis
(Fas ligand, Fas, and caspase 4), p53-like proteins
(p73, p63), positive regulators of apoptosis and NF-
5B activation (CARD10, CARD14), and cyclin-
dependent kinase inhibitors (p16 and p18). These
data demonstrate potent and speciﬁc anti-myeloma
activity of EGCG and provide the rationale for its
clinical evaluation.
EGCG also induces cell death in acute myeloid
leukaemia (AML) patient samples while granulocytes
and PBMC from healthy donors were not aﬀected by
EGCG. AML cells express the 67LR while normal
controls does not express the receptor. Moreover,
the susceptibility of AML patient samples has been
shown to be closely associated with the level of 67LR
expression.61)
On the other hand, EGCG has been shown to
inhibit cell death of muscle cells. Duchenne muscular
dystrophy is a fatal muscle wasting disease caused
by the absence of the protein dystrophin. 67LR was
seven times more abundant in dystrophic muscle
cells compared with normal cells. EGCG protected
primary dystrophic muscle cells from oxidative
damage induced by hydrogen peroxide in the widely
used mdx mouse model but could not protect normal
cells.62)
Anti-allergic action of EGCG through the 67LR
Mast cells and basophils play a central role in
immediate allergic reactions mediated by IgE. Bind-
ing of multivalent allergens to speciﬁc IgE attached
to the FcCRI on the surface of mast cells or basophils
leads to the release of both preformed and newly
generated inﬂammatory mediators such as histamine.
These mediators ultimately cause various symptoms
including atopic dermatitis, bronchial asthma, and
food allergy.63),64) The early phase of cell activation of
mast cells and basophils includes the phosphorylation
and activation of protein tyrosine kinases and their
substrates, generation of the second messengers such
as inositol trisphosphate and diacylglycerol, and
elevation of intracellular Ca2D levels.65),66) The late
phase of the activation, which occurs after the inﬂux
of Ca2D, includes the fusion of secretory granules with
the membrane and dramatic morphological changes
due to remodeling of actin cytoskeleton, which
undergo extensive membrane ruﬄing.67)–69) We found
that EGCG inhibited the calcium ionophore A23187-
induced histamine release from the human basophilic
KU812 cells and could not inhibit the increase of
the intracellular Ca2D level after stimulation with
A23187.70) This result suggested that the eﬀect of
EGCG on histamine release occurs after the elevation
of the intracellular Ca2D concentration. Thr18/Ser19
phosphorylation of MRLC has been reported to be
temporally correlated with degranulation in the
rat basophilic RBL-2H3 cells, and the inhibition of
MRLC phosphorylation has been shown to impair
the degranulation.71) Although EGC, having no
ability to inhibit histamine release, showed no
inhibitory eﬀect on MRLC phosphorylation, EGCG
clearly reduced the level of phosphorylated MRLC.70)
After treatment of KU812 cells with the anti-67LR
antibody, cells were incubated with EGCG, and
further challenged with A23187. The reductive eﬀect
of EGCG on the histamine release was almost
completely inhibited in cells treated with the anti-
67LR antibody. Experiment using such 67LR-down-
regulated cells revealed a signiﬁcant abrogation of
the inhibitory eﬀect of EGCG on degranulation.
Furthermore, the lowering eﬀect of EGCG on the
phosphorylation of MRLC was also inhibited by
either treatment with the anti-67LR antibody or
67LR-knockdown. These ﬁndings indicate that the
inhibitory eﬀect of EGCG on degranulation was
caused by a modiﬁcation of myosin cytoskeleton
through the binding of EGCG to 67LR on the cell
surface (Fig. 3). When the basophilic cells were
stimulated with A23187 in the presence of EGCG
(25µmol/L), membrane ruﬄing was inhibited and a
biased F-actin accumulation was observed. Further-
more, this EGCG-induced actin remodeling was
abolished in both anti-67LR antibody-treated cells
and 67LR-knockdowned cells.70) Our ﬁndings indi-
cated that EGCG-induced actin remodeling is caused
by lowering MRLC phosphorylation mediated
through the binding of EGCG to the 67LR. Thus,
these cytoskeletal modiﬁcations may have an impor-
tant role in the inhibition of histamine release by
EGCG.
FcCRI plays a central role in the induction and
maintenance of IgE mediated allergic responses such
as atopic dermatitis, bronchial asthma, and food
allergy. Analysis of , chain-deﬁcient mice demon-
strated that IgE was unable to bind to the cell sur-
face of mast cells, thereby inabling the induction of
degranulation through IgE binding.72) Thus, it is
expected that the downregulation of FcCRI expres-
sion in mast cells and basophils may lead to the
attenuation of the IgE-mediated allergic symptoms.
We found that EGCG was able to decrease the
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KU812 cells. Total cellular expression of the FcCRI ,
chain decreased upon treatment with EGCG. We
also found that EGCG has an ability to inhibit the
phosphorylation of the extracellular signal-regulated
kinase1/2 (ERK1/2).33) This inhibition was involved
in downregulation of FcCRI expression by EGCG.
Moreover, the inhibitory eﬀect elicited by EGCG on
ERK1/2 was prevented by disruption of lipid rafts.
Accordingly, the interaction between EGCG and
the lipid rafts is important for EGCG’s ability to
downregulate FcCRI expression, and ERK1/2 may be
involved in this suppression signal. We also demon-
strated that the suppressive eﬀect of EGCG was
inhibited by the knockdown of 67LR. Furthermore,
the ability of EGCG to decrease the phosphorylation
of ERK1/2 was reduced in the 67LR-knocked down
cells. These results indicate that the eﬀect of EGCG
on ERK1/2 phosphorylation correlates with the
expression of 67LR, which implies that the 67LR is
the molecule responsible for transducing the EGCG’s
downregulatory signaling of the FcCRI (Fig. 3).
The O-methylated derivative of EGCG, (!)-epi-
gallocatechin-3-O-(3-O-methyl)-gallate (EGCG3′′Me)
and (!)-epigallocatechin-3-O-(4-O-methyl)-gallate
(EGCG4′′Me), which were isolated from tea leaves
such as Tong-ting oolong tea or cultivars ‘Benifuuki’
has been shown to inhibit allergic reactions
in vitro.73),74) The inhibitory eﬀects of O-methylated
EGCG on mouse type I and IV allergies in vivo more
potently than EGCG.73),75) These catechins also
strongly inhibited mast cell activation through the
prevention of tyrosine phosphorylation (Lyn, Syk
and Btk) of cellular protein and histamine/leuko-
triene release, interleukin-2 secretion after FcCRI
cross-linking.76) A double-blind clinical trial to treat
allergic cedar pollinosis patients with ‘Benifuuki’
green tea rich in EGCG3′′Me was carried out, and
promising results have been obtained by using a
protocol of drinking of 1.5g of tea powder with water
twice a day for 13 weeks.77) We have been found
that EGCG3′′Me can inhibit histamine release and
suppress the FcCRI expression in human basophilic
KU812 cells the same as EGCG.74),78) RNAi-medi-
ated knockdown of 67LR expression resulted in a
decreased activity of EGCG3′′Me.79) The suppression
of MRLC phosphorylation through the cell-surface
binding to the 67LR contributes to the inhibitory
eﬀect of EGCG3′′Me on the histamine release. The
67LR also mediated the EGCG3′′Me-induced sup-
pression of FcCRI expression by reducing ERK1/2
phosphorylation.
EGCG is known to be unstable and is degrad-
ed easily in animal bodies. On the other hand,
EGCG3′′Me and EGCG4′′Me are absorbed eﬃciently
and are more stable than EGCG in animal and human
plasma, suggesting the reason for the methylated
derivatives of EGCG having potent inhibitory activ-
ities to allergies in vivo. EGCG has been reported to
undergo methylation, and (!)-4′-O-methyl-epigallo-
catechin-3-O-(4-O-methyl) gallate (EGCG4′4′′diMe)
has been shown to be a major metabolite of EGCG in
plasma,80) and EGCG4′4′′diMe did not demonstrate
a suppressive eﬀect in KU812 cells.81) Although our
studies on methylated EGCGs may contribute to
the elucidation of physiological activities of EGCG
in vivo, further investigation of the relationship
between metabolites of EGCG and 67LR is necessary
for a better understanding of the molecular basis of
EGCG activities in vivo.
Anti-inﬂammatory action of EGCG
through the 67LR
EGCG has been shown to rescue mice from
Lipopolysaccharide (LPS)-induced lethal endo-
toxemia and downregulate inﬂammatory responses
in macrophages.82) LPS is one of the most powerful
activators of Toll-like receptor (TLR) 4 signaling,
and is also well known to induce production of
inﬂammatory mediators through the receptor. Re-
cently, we found the molecular basis for the down-
regulation of TLR4 signal transduction by EGCG at
1µM in macrophages.83) Anti-67LR antibody treat-
ment or RNAi-mediated silencing of 67LR resulted in
abrogation of the inhibitory action of EGCG on LPS-
induced activation of downstream signaling path-
ways and target gene expressions in murine macro-
phages. Additionally, we found that EGCG reduced
the TLR4 expression through 67LR. Interestingly,
EGCG induced a rapid upregulation of Tollip
protein, a nagative regulator of TLR-signaling, and
this EGCG action was prevented by 67LR silencing
or anti-67LR antibody treatment. RNAi-mediated
silencing of Tollip impaired the TLR4 signaling
inhibitory activity of EGCG. Taken together, these
ﬁndings demonstrate that 67LR plays a critical role
in mediating anti-inﬂammatory action of a physio-
logically relevant EGCG and Tollip expression could
be modulated through 67LR in macrophages.
Modulation of insulin action by EGCG
through the 67LR
Insulin is a key factor in stimulating fat
cell mitogenesis and adipogenesis.84) Green tea
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tive agents for obesity and modulators of fat cell
growth.85),86) In particular, EGCG has been shown to
reduce body weight and body fat in vivo.87) EGCG
inhibited insulin stimulation of murine preadipocyte
proliferation. EGCG also suppressed insulin-stimu-
lated phosphorylation of the insulin receptor-O,
insulin receptor (IR) substrates 1 and 2 (IRS1 and
IRS2), and mitogen-activated protein kinase path-
way proteins. Pretreatment of preadipocytes with
67LR antiserum prevented the eﬀects of EGCG on
insulin-stimulated phosphorylation of IRS2, RAF1,
and ERK1/2 and insulin-stimulated preadipocyte
proliferation. Moreover, EGCG tended to increase
insulin-stimulated associations between the 67LR
and IR, IRS1, IRS2, and IRS4 proteins. These data
suggest that EGCG mediates anti-insulin signaling
in preadipocyte mitogenesis via the 67LR. However,
higher EGCG concentrations are needed to modulate
insulin action. The applicability of this observation
remains to be investigated.
Inhibition of tissue factor expression by EGCG
through the 67LR in aortic endothelial cells
Tissue factor (TF) is an important trigger of
arterial thrombosis.88) EGCG exhibits cardioprotec-
tive eﬀects and inhibits TNF-,- and histamine-
induced endothelial TF expression and activity.89)
In vivo administration of EGCG (30mg/kg/day)
inhibited TF activity in carotid arteries of C57BL6
mice. EGCG decreased TF expression at the tran-
scriptional level and impaired activation of the JNK
1/2. Human aortic endothelial cells expressed 67LR,
and 67LR-blocking antibodies blunted the inhibitory
eﬀect of EGCG on both TF protein expression and
JNK activation. This leads to a prediction that
EGCG-elicited 67LR activation inhibits endothelial
TF expression by impairing JNK phosphorylation.
Green tea polyphenol sensing molecules
In an attempt to elucidate the pathways
involved in the anticancer action of EGCG, we
applied genetic suppressor element (GSE) method-
ology. GSEs are short cDNA fragments encoding
peptides acting as dominant inhibitors of protein
function or antisense RNAs inhibiting gene expres-
sion. GSEs behave as dominant selectable markers
for the phenotype associated with the repression of
the gene from which they derived, thus allowing
identiﬁcation of this gene. For identifying genes
mediating cell sensitivity to EGCG, we selected
GSEs conferring resistance to EGCG. To search for
the mediators of EGCG-induced cell growth inhib-
ition in B16 mouse melanoma cells, we utilized a
targeted genetic screen with a GSE complementary
DNA library. Among genetic elements protecting
cells from EGCG-induced cell growth inhibition, we
isolated a GSE that encoded the N terminus of
eukaryotic translation elongation factor 1A (eEF1A).
eEF1A is an important component of the eukaryotic
translation apparatus and is also known as a multi-
functional protein that is involved in a large number
of cellular processes.90)
To investigate the role of eEF1A in EGCG-
induced cell growth inhibition, we used stable RNAi
to silence eEF1A expression in B16 cells. Remark-
ably, silencing of eEF1A attenuated the inhibitory
eﬀect of 1µM EGCG on cell growth.14) In contrast,
overexpression of eEF1A enhanced the inhibitory
eﬀects of 1µM EGCG on cell growth. This concen-
tration is similar to the amount of EGCG found in
human plasma after drinking more than two or three
cups of green tea. Given this, we investigated the
eﬀect of oral administration of EGCG on subcuta-
neous tumor growth in C57BL/6N mice challenged
with eEF1A-ablated B16 cells.14) Tumor growth was
signiﬁcantly retarded in EGCG-administered mice
implanted with the B16 cells harboring a control
shRNA, whereas tumor growth was not aﬀected by
EGCG in the mice implanted with eEF1A-ablated
B16 cells, indicating that eEF1A is involved in
EGCG-induced cancer prevention. These results
support our conclusion that eEF1A serves as a
mediator for EGCG-induced cancer prevention.
As described previously, EGCG-induced cell
growth inhibition may result from the reduction
of the phosphorylation of MRLC at Thr-18/Ser-19
through 67LR.21) The activity of myosin phosphatase
is known to be inhibited by phosphorylation of its
targeting subunit MYPT1 at Thr-696 and Thr-
853.91) We tested the eﬀect of EGCG on the
phosphorylation of MYPT1 at Thr-696 and Thr-
853. Intriguingly, although the phosphorylation level
at Thr-853 was unaﬀected by EGCG, EGCG induced
the dephosphorylation of MYPT1 at Thr-696.
Further, this eﬀect correlated with EGCG-induced
reduction of the MRLC phosphorylation, suggesting
that EGCG activates myosin phosphatase by reduc-
ing the MYPT1 phosphorylation level at Thr-696.
Next, we investigated whether MYPT1 is involved in
anticancer action of EGCG in vivo. In B16 cells,
physiological concentrations of EGCG reduced the
MYPT1 phosphorylation at Thr-696 and the MRLC
phosphorylation. We conﬁrmed both silencing of
H. TACHIBANA [Vol. 87, 74MYPT1 by stable RNAi in B16 cells and attenuation
of the inhibitory eﬀect of 1µM EGCG on cell growth
in MYPT1-ablated B16 cells in vitro. We tested the
eﬀect of oral administration of EGCG on subcuta-
neous tumor growth in C57BL/6N mice challenged
with MYPT1-ablated B16 cells.14) Tumor growth
was signiﬁcantly retarded in EGCG-administered
mice implanted with the B16 cells harboring a control
shRNA, whereas tumor growth was not aﬀected by
EGCG in the mice implanted with MYPT-1-ablated
B16 cells, suggesting that MYPT1 is indispensable
for EGCG-induced cancer prevention.
In both 67LR-ablated HeLa cells and eEF1A-
ablated HeLa cells, the inhibitory eﬀect of EGCG
on both the phosphorylation of MYPT1 at Thr-696
and the phosphorylation of MRLC was attenuated.
In addition, EGCG-induced actin cytoskeleton rear-
rangement was no longer observed in MYPT1-,
eEF1A-, or 67LR-ablated HeLa cells. The involve-
ment of MYPT1 in downstream EGCG-triggered
signaling from both 67LR and eEF1A was further
documented by conﬁrming abrogation of 1µM
EGCG-induced reduction of the MYPT1 phospho-
rylation level at Thr-696 and the MRLC phospho-
rylation in 67LR- or eEF1A-ablated B16 cells. These
results suggest that MYPT1 is involved in down-
stream EGCG signaling from both 67LR and eEF1A
(Fig. 4). It has been reported that MYPT1 binds to
eEF1A,92) and more than half of the total eEF1A
(>60%) binds to the actin cytoskeleton.93) Character-
Fig. 4. The signaling pathways that sense and respond to EGCG through 67LR are depicted. After EGCG binding to lipid raft-
associated 67LR, through eEF1A, the phosphorylation of MYPT1 at Thr-696 but not Thr-853 is reduced, which leads to the
activation of myosin phosphatase. The activated myosin phosphatase dephosphorylates its substrates (e.g. MRLC), and actin
cytoskeleton rearrangement is induced. The alteration of actin cytoskeleton might lead to cell growth inhibition. EGCG also induces
apoptosis in the 67LR-expressing cells derived from multiple myeloma and acute myeloid leukaemia patient samples.
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reduction of the MYPT1 phosphorylation at Thr-
696 and reorganization of actin cytoskeleton through
eEF1A should help in more precise understanding of
cytoskeleton organization.
Conclusions
Beneﬁcial health eﬀects by edible phytochem-
icals is now considered to be an inexpensive, readily
applicable, acceptable, and accessible approach to
cancer control and management,94) however, little is
known about the mechanism of the chemopreventive
action of most phytochemicals. Here we described
that 67LR is a critical sensor molecule to respond to
EGCG and mediate the beneﬁcial activities of this
phyrochemical. eEF1A and MYPT1 are also EGCG-
sensing molecules for EGCG-elicited cancer preven-
tion at physiological concentrations. More deﬁnitive
information on the relationship between EGCG
sensing-pathways and beneﬁcial eﬀects of EGCG
ingestion will emerge from cohort studies and human
intervention trials. We hope that this review will
have wide-ranging implications, as many of the issues
discussed here might also be applicable to studies of
other dietary ingredients.
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